Telotristat Etiprate for Carcinoid Syndrome Therapy

Inclusion Criteria:

   - Patients ≥ 18 years of age

   - All patients of reproductive potential must agree to use an adequate method of
   contraception during the study and for 12 weeks after the Follow-up visit.

   - Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor

   - Documented history of carcinoid syndrome

   - Patient is able and willing to provide written informed consent prior to participation

Exclusion Criteria:

   - Presence of diarrhea attributed to any condition other than carcinoid syndrome.

   - Presence of 12 or more watery bowel movements per day

   - Positive stool examination for enteric pathogens, pathogenic ova or parasites, of
   Clostridium difficile at Screening

   - Karnofsky Performance Status ≤ 60%

   - Presence of any clinically significant laboratory, medical history, or physical
   examination findings deemed unacceptable by the Investigator

   - A history of short bowel syndrome

   - History of constipation within 2 years of Screening

   - Life expectancy < 12 months from Screening